Toronto-based 1DegreeBio closes Series B funding round with Macmillan Digital Science

Share Article

Funding will support 1DegreeBio expansion plans in the coming year

1DegreeBio Inc., the largest independent review website for research-grade antibodies and related life science products has closed a Series B round of funding, led by Macmillan Digital Science Limited. Philip Armstrong, CEO of Jovian Capital Corporation, and 1DegreeBio senior management also participated in the round.

The funding announcement follows a year of exceptional growth by 1DegreeBio, which has increased its user base from 23,000 to more than 75,000 users, and increased its product database from 400,000 products to more than 800,000 since July 2011.

"We are delighted to have the continued support of Digital Science and Philip Armstrong," said Alex Hodgson, Managing Director, 1DegreeBio. "Our growth has been even greater than anticipated; in the last year we’ve tripled our user base and more than doubled our product listings. It would not have been possible without the passion of the 1DegreeBio team, the support of our funders and the scientific community that has stood behind us from day one."

1DegreeBio is among Digital Science's portfolio companies, which also include SureChem, Labtiva, BioData, BioRAFT, figshare and Symplectic. Together they support Digital Science’s mandate to provide cutting edge software and technology to make scientific research more efficient.

“1DegreeBio has proven a tremendously valuable resource to the research community,” said Timo Hannay, Managing Director, Digital Science. “We are pleased to have them as part of the Digital Science family, and look forward to seeing even more developments in their offering in the year to come.”

Following on the launch of its Epigenetics Portal on June 4, 1DegreeBio will be launching a series of other specialized portals to support specific research areas over the next few months. The coming year will also see expansion into other life science product types and services, in addition to conducing new market research around the life science community.

"It’s an exciting time at 1DegreeBio – from new collaborations and outreach initiatives to new tools and expansion plans,” said Hodgson. “This next year is going to knock your socks off."

About 1DegreeBio Inc. is the world’s largest open-access antibody database. Listing more than 800,000 products from 160 suppliers, 1DegreeBio has all the information researchers need to find the right products for their research, including quality validation data, citations, user reviews and ratings.

About Digital Science

Digital Science is a division of Macmillan Publishers Ltd., launched in December 2010 to provide technology solutions for researchers. From intelligent knowledge discovery tools to software applications for the laboratory and decision-support systems for managers, Digital Science combines world-class technology with a resolute focus on scientists and those who support the research process. For more information, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sarah Bannoff
Visit website